Story thread · 3 reports / 3 sources
Ozempic’s maker is in trouble. Tablets may be the answer
smh.com.au · 12d · first report
How the coverage leans
Across 3 sources · syndicated copies counted once
Just a few years ago, Novo Nordisk was the darling of the healthcare industry. Now it is teetering.
The conversation · 0
Sign in to join the conversation.
No comments yet — start the thread.